文献速递浆细胞疾病

卡非佐米诱导的内皮功能障碍、蛋白酶体活性恢复与心血管并发症预测:一项前瞻性研究

Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study.
PubMed 文献 · Leukemia · 2021-02-15

结果显示卡非佐米急性损害内皮功能并与PrA抑制及恢复相关,基线和治疗中FMD变化均可独立预测≥3级心血管不良事件。

要点

  • 卡非佐米首剂后FMD和PrA急性下降,第3和6周期FMD较基线降低。
  • 基线FMD最低三分位者心血管事件风险增高(HR 2.57)。
  • 首周期FMD下降>40%独立预测心血管事件(HR 3.91)。

核心结论

  • Kd方案损害内皮功能,且与蛋白酶体活性抑制及恢复相关。
  • 基线和治疗后FMD均可预测卡非佐米相关心血管不良事件,可能作为毒性生物标志物。

研究设计与样本

  • 系列评估肱动脉血流介导舒张(FMD)和外周血单核细胞26S蛋白酶体活性(PrA),随访至疾病进展或第6周期,中位10个月。

主要发现

  • 首剂后FMD和PrA急性下降(p < 0.01),第3和6周期FMD较基线下降(p ≤ 0.05)。
  • FMD变化与卡非佐米诱导的PrA变化相关(p < 0.05),首周期PrA恢复较低与FMD下降更显著相关(组间交互p = 0.034)。
  • 治疗期间25例患者发生≥3级心血管不良事件。
  • 低基线FMD(最低三分位 vs 较高三分位)是心血管不良事件的独立预测因子(HR 2.57,95% CI 1.081-6.1)。
  • 首周期结束时FMD急性下降>40%亦独立与心血管不良事件相关(HR = 3.91,95% CI 1.29-11.83)。

临床怎么用

  • 可考虑通过基线和治疗早期FMD评估卡非佐米治疗患者的心血管毒性风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Carfilzomib (CFZ) improves survival in relapsed/refractory multiple myeloma but is associated with cardiovascular adverse events (CVAEs). We prospectively investigated the effect of CFZ on endothelial function and associations with CVAEs. Forty-eight patients treated with Kd (CFZ 20/56 mg/m2 and dexamethasone) underwent serial endothelial function evaluation, using brachial artery flow-mediated dilatation (FMD) and 26S proteasome activity (PrA) measurement in PBMCs; patients were followed until disease progression or cycle 6 for a median of 10 months. FMD and PrA decreased acutely after the first dose (p < 0.01) and FMD decreased at cycles 3 and 6 compared to baseline (p ≤ 0.05). FMD changes were associated with CFZ-induced PrA changes (p < 0.05) and lower PrA recovery during first cycle was associated with more prominent FMD decrease (p = 0.034 for group interaction). During treatment, 25 patients developed Grade ≥3 CVAEs. Low baseline FMD (HR 2.57 lowest vs. higher tertiles, 95% CI 1.081-6.1) was an independent predictor of CVAEs. During treatment, an acute FMD decrease >40% at the end of first cycle was also independently associated with CVAEs (HR = 3.91, 95% CI 1.29-11.83). Kd treatment impairs endothelial function which is associated with PrA inhibition and recovery. Both pre- and posttreatment FMD predicted CFZ-related CVAEs supporting its role as a possible cardiovascular toxicity biomarker.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kastritis E, Laina A, Georgiopoulos G, et al. Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. Leukemia. 2021. PMID: 33589757. doi:10.1038/s41375-021-01141-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。